Is a complete LYEL research report available?

No complete published report is available for Lyell Immunopharma, Inc. (LYEL) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · USD

$13.7

+0.75 (+5.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first LYEL analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	336.2M
Revenue (ttm)	31K
Net income (ttm)	-246.4M
EPS (ttm)	-$13.1
Shares out	24.5M
Volume	197,918
Beta	-0.06
Price target	$38.1	+178.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 31K
Net income (ttm): -246.4M
EPS (ttm): -$13.1
Market cap: 336.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All LYEL indicators

Market & fundamental data

Available fields

208

Groups with data

Currency

USD

Showing 208 of 208 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001806952
Company name	Lyell Immunopharma, Inc.
Country	United States
Country code	US
Cusip	55083R203
Employees	161
Employees Change	-139%
Employees Change Percent	-46.33
Enterprise value	$124.1M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-06-17
Isin	US55083R2031
Last refreshed	2026-07-31
Market cap	$336.2M
Market cap category	Small-Cap
Price	$13.72
Price currency	USD
Rev Per Employee	192.55x
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	LYEL
Website	https://www.lyell.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-73.29%
EV Sales Forward	8,009.93x
EV/Sales	4,002.38x
FCF yield	-39.98%
P/B ratio	1.17x
P/S ratio	10,845.15x
PS Forward	21,704.31x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-826,767.74%
EBITDA Margin	-793,122.58%
Gross margin	100%
Gross Profit	$31,000
Gross Profit Growth	-52.31%
Gross Profit Growth Q	-71.43%
Gross Profit Growth3 Y	-92.83%
Gross Profit Growth5 Y	-67.79%
Net Income	$-246.4M
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Pretax Margin	-794,858.06%
Profit Per Employee	$-1.5M
ROA	-29.87
Roa5y	-18.9
ROCE	-81.71
ROE	-80.76
Roe5y	-47.15
ROIC	-32.55

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	6.61%
Cagr3y	-38.43%
Cagr5y	-45.27%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth	-52.31x
Revenue Growth Q	-71.43x
Revenue Growth Years	0x
Revenue Growth3 Y	-92.83x
Revenue Growth5 Y	-67.79x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0
Assets	$350.6M
Cash	$254M
Current Assets	$267.3M
Current Liabilities	$36.9M
Debt	$48.9M
Debt Equity	$0.18
Equity	$273.7M
Liabilities	$77M
Long Term Assets	$83.3M
Long Term Liabilities	$40M
Net Cash	$212.1M
Net Cash By Market Cap	$63.1
Net Cash Growth	-22.31%
Net Debt Equity	$-0.78
Tangible Book Value	$273.7M
Tangible Book Value Per Share	$11.73
WACC	3.41

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.23
Net Working Capital	$-14.3M
Quick ratio	6.88
Working Capital	$230.4M
Working Capital Turnover	$0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-38.93%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	6.61%
200-day SMA	20.65
3Y total return	-76.67%
50-day SMA	13.98
50-day SMA vs 200-day SMA	50under200
5Y total return	-95.09%
All Time High	396.8
All Time High Change	-96.54%
All Time High Date	2021-09-07
All Time Low	7.65
All Time Low Change	79.35%
All Time Low Date	2025-06-02
ATR	1.02
Beta	-0.06
Beta1y	2.35
Beta2y	1.81
Ch YTD	-55.43
High	13.74
High52	45
High52 Date	2025-12-22
High52ch	-69.51%
Low	12.82
Low52	9.28
Low52 Date	2025-08-13
Low52ch	47.85%
Ma50ch	-1.85%
Price vs 200-day SMA	-33.56%
RSI	50.65
RSI Monthly	37.1
RSI Weekly	41.83
Sharpe ratio	0.43x
Sortino ratio	0.71
Total Return	-38.93%
Tr YTD	-55.43
Tr1m	7.61%
Tr1w	7.36%
Tr3m	-33.4%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	4
Analyst Price Target Top	$36.25
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-2
Earnings Revenue Estimate	4,600x
Earnings Revenue Estimate Growth	-42.5x
Operating Income	$-186.5M
Operating margin	-601,516.1
Price target	$38.14
Price Target Change	$178
Price Target Change Top	$164

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10,873,900%
Float Percent	44.38%
Shares Insiders	7.18%
Shares Institutions	31.75%
Shares Out	24,504,358
Shares Qo Q	6.63%
Shares Yo Y	38.93%
Short Float	11.22%
Short Ratio	4.65
Short Shares	4.98

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-174.5M
Adjusted OCF	-173,896,000
Average Volume	163,870x
Bv Per Share	11.73
CAPEX	$-623,000
Ch1m	7.61
Ch1w	7.36
Ch1y	6.61
Ch3m	-33.4
Ch3y	-76.67
Ch5y	-95.09
Ch6m	-44.7
Change	5.78%
Change From Open	5.7
Close	12.97
Days Gap	0.08
Depreciation Amortization	10,430,000
Dollar Volume	2,715,435
Earnings Date	2026-08-05
Earnings Time	amc
EBIT	$-256.3M
EBITDA	$-245.9M
EPS	$-13.06
F Score	1
FCF	$-134.4M
FCF EV Yield	-108.34x
FCF Per Share	$-5.49
Financing CF	102,127,000
Fiscal Year End	December
Founded	2,018
Investing CF	2,009,000
Ipr	-19.29
Iprfo	-96.34
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Date	2025-06-02
Last Split Type	Reverse
Last10k Filing Date	2026-03-12
Ma150	20.31
Ma150ch	-32.44%
Ma20	13.79
Ma20ch	-0.49%
Net CF	-29,660,000
Next Earnings Date	2026-08-11
Open	12.98
Optionable	Yes
Position In Range	97.83
Ppne	50,548,000
Price Date	2026-07-30
Ptbv Ratio	1.23
Relative Volume	1.21x
Revenue	31,000x
SBC By Revenue	129,354.84x
Share Based Comp	40,100,000
Tr6m	-44.7%
Us State	California
Volume	197,918
Z Score	-5

Lyell Immunopharma, Inc. (LYEL)

Coverage state: Market snapshot only — no published research

Generate the first LYEL analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · LYEL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LYEL indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on LYEL

Frequently asked questions